GN-CORPORATION
12.10.2021 08:37:04 CEST | Business Wire | Press release
Cytokine storm and coagulopathy, the major life-threatening complications of COVID-19, whose biomarkers Interleukin-6 and D-Dimer were under control with consumption of two variants of Nichi Glucan food supplements from Japan in a pilot study. Immune parameters like ratios of neutrophil to lymphocyte (NLR ), lymphocyte to c-reactive protein (LCR ) and leucocyte to c-reactive protein (LeCR ) were advantageous, along with CD4 and CD8 levels, in those who consumed Nichi Glucans than, those who didn’t, as published in Biomedicine and Pharmacotherapy, a peer reviewed journal (https://www.sciencedirect.com/science/article/pii/S0753332221010271 ).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211011005726/en/
The Covid-19 infection by SARS-COV-2 virus leads to several complications and those have succumbed to the illness developed cytokine storm because of an overreacting immune system, that should be tackled with immunomodulation. According to Dr Raghavan, the first author of the publication, the AFO-202 strain of Black Yeast Aureobasidium Pullulans produced Nichi-Glucan enhances the immune system, while the N-163 strain produced Nichi-Glucan REFIX, efficiently modulates immunity, avoiding any catastrophe. Their combination has yielded this encouraging outcome and our interpretations are based on the present study as well as pre-clinical and clinical studies in healthy volunteers, he added (https://doi.org/10.1101/2021.08.05.21261640 ).
Criteria such as NLR, LCR and LeCR have recently gained significance in assessing Covid-19 severity, which we have documented to be advantageous with Nichi Glucan consumption in healthy people and pre-clinically as well (https://www.researchsquare.com/article/rs-771315/v1 ). Having been proven to handle the immune system in a balanced manner and with potentials of Beta glucans to act through microglia of the brain (Journal of the neurological sciences; https://www.jns-journal.com/article/S0022-510X(21)00248-3/fulltext ), the Nichi glucan variants, with a safety track record of more than two decades may help tackle long Covid-19 also, concludes the study.
In the 1980s, evolution inspired, Prof Noboru Fujii started exploring this poly-extremo tolerant fungus, that was nature gifted . Positioned in the tree of life between animal and plant kingdom, the R&D team believes that the symbiosis of this prebiotic product with gut microbiome may unravel the mechanisms behind its multiple beneficial effects to human health.
GN Corporation, holding the exclusive global distribution rights of the Nichi Glucans, are pursuing elaborate research in bringing out the hidden potentials of several strains of this black yeast fungi produce and plan to undertake larger studies.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211011005726/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva26.9.2026 01:00:00 CEST | Press release
-Once-daily oral ALK2 inhibitor approved to reduce the volume of total new heterotopic ossification in patients aged 12 years and older with FOP-Atebrioz expected to be available in the United States in October through Mirum Access Plus (MAP), with eligible patients paying as little as $0 per month-PROGRESS pediatric development program continues to evaluate zilurgisertib in children aged 2 to <12 years Mirum Pharmaceuticals, Inc. (Nasdaq:MIRM) and Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Atebrioz™ (zilurgisertib) tablets to reduce the volume of total new heterotopic ossification (HO) in adult and pediatric patients aged 12 years and older with fibrodysplasia ossificans progressiva (FOP). The recommended dose of Atebrioz is 100 mg administered orally, once daily. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260925436454/en/ “Today marks an important milestone for pe
Digital Reef Signs Offtake Agreement with Oreasoc Agriculture to Mitigate the Environmental Footprint of Data Centre Growth Through Rainforest Protection, Appointing Xange.com as Digital MRV Partner25.9.2026 21:19:00 CEST | Press release
The offtake agreement connects Digital Reef’s 3.3 GW data centre pipeline with environmental assets from more than 30 million hectares of Amazon rainforest across South America, where Oreasoc Agriculture works directly on the ground alongside local communities to develop sustainable economies and safeguard their territories. Xange.com’s digital MRV technology monitors both the data centres and the rainforest. At Climate Week NYC, Digital Reef and Oreasoc Agriculture Inc. sign an offtake agreement connecting Digital Reef’s 3.3 GW data centre pipeline with environmental assets exceeding 30 million hectares of South American Amazon rainforest, mitigating the environmental footprint of data centre growth through rainforest protection and restoration where Oreasoc works alongside local communities to protect biodiversity, develop sustainable economies and safeguard their territories. Xange.com are appointed as digital MRV technology partner to monitor the data centres and rainforest where D
NetApp Announces Intent to Acquire PEAK:AIO to Advance Scalable AI Infrastructure Architecture25.9.2026 15:00:00 CEST | Press release
Planned acquisition strengthens NetApp's position in the rapidly growing AI infrastructure market by bringing differentiated metadata innovation and parallel file architecture designed for AI NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced its intent to acquire PEAK:AIO, a pioneer in next-generation metadata architecture and high-performance parallel file systems. The planned acquisition is expected to accelerate NetApp's AI infrastructure roadmap by augmenting metadata services and parallel namespace innovation designed to help AI clouds scale shared storage alongside growing GPU clusters. As AI becomes embedded in every enterprise workload, organizations are confronting a new challenge: traditional storage architectures were not designed for the unprecedented scale, concurrency, and performance requirements of AI factories, AI clouds, and next-generation data-intensive applications. NetApp is building an architecture that disaggregates metadata fr
MultiBank Group Secures Two Awards at Forex Expo Dubai 202625.9.2026 14:57:00 CEST | Press release
The Group was recognised for the strength of its global institutional ecosystem and its contribution to financial markets innovation and community impact MultiBank Group, one of the world’s largest financial derivatives institutions, received two awards during its participation at Forex Expo Dubai 2026, held on 22 and 23 September at Dubai World Trade Centre. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260925539591/en/ MultiBank Group was named “Best Global Institutional Financial Ecosystem of the Year” and received the award for “Excellence in Global Financial Markets Innovation and Community Impact.” The Group was named “Best Global Institutional Financial Ecosystem of the Year” and received the award for “Excellence in Global Financial Markets Innovation and Community Impact.” The first award recognised the strength and breadth of MultiBank Group’s global institutional offering, which brings together trading, liquidity
Croma-Pharma Introduces saypha® volume prime Lidocaine25.9.2026 14:04:00 CEST | Press release
New cross-linked hyaluronic acid filler replaces saypha® volume Lidocaine, offering physicians a more versatile solution for both midface volumization and nasolabial folds Croma-Pharma introduces saypha® volume prime Lidocaine, a cross-linked hyaluronic acid dermal filler that replaces saypha® volume Lidocaine within the company's saypha® portfolio. The new product offers physicians a more versatile solution with expanded indications for both midface volumization and nasolabial folds, backed by strong clinical data. 1,2 saypha® volume prime Lidocaine demonstrated non-inferiority to comparatora in a randomized, subject- and evaluator-blinded, controlled, non-inferiority multicenter, parallel group comparison study with almost 500 patients.2 In the clinical evaluation, a high patient satisfaction highlights improved midface fullness, smoothness and contour, consistent with a rheologic profile designed to provide volumization in the mobile midface.b,2 With saypha® volume prime Lidocaine,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
